Looking at the universe of stocks we cover at Dividend Channel, on 4/26/13, Full Circle Capital Corp (FULL) will trade ex-dividend, for its monthly dividend of $0.077, payable on 5/15/13. As a percentage of FULL's recent stock price of $7.98, this dividend works out to approximately 0.96%, so look for shares of Full Circle Capital Corp to trade 0.96% lower — all else being equal — when FULL shares open for trading on 4/26/13.Below is a dividend history chart for FULL, showing historical dividends prior to the most recent $0.077 declared by Full Circle Capital Corp: In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from FULL is likely to continue, and whether the current estimated yield of 11.58% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of FULL shares, versus its 200 day moving average: Looking at the chart above, FULL's low point in its 52 week range is $6.68 per share, with $8.50 as the 52 week high point — that compares with a last trade of $7.98. In Wednesday trading, Full Circle Capital Corp shares are currently trading flat on the day.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Which Technology Stocks Make Better Investments During a Trade War?
Here's your playbook for gearing a long-term portfolio during a trade war.
Alphabet Stock Is Just Too Cheap After Its Recent Sell-Off
The tech giant remains an absolute cash cow with over $113 billion on the balance sheet and trades for a reasonable 25x forward earnings. The post-earnings sell-off is over done.
Merck to Acquire Peloton Therapeutics for About $1B in Cash
Merck agrees to buy privately held Peloton Therapeutics for $1 billion in cash, giving it access to Peloton's molecular therapy treatments for patients with cancer and other non-oncology diseases.
Home Depot, Kohl's, Nike, General Motors and Huawei - 5 Things You Must Know
U.S. stock futures rise after the U.S. eases restrictions on China's Huawei; Nike leads a group of athletic apparel and shoe companies in an effort to urge Donald Trump to reconsider placing tariffs on footwear; Home Depot, Kohl's and Nordstrom report earnings.